Fig.1 4% DSS induced IBD model in C57BL/6 female or male mice. (A) Body weight. (B) DAI Score.?
Fig.2 4% DSS induced IBD model in C57BL/6 female or male mice. (A) Spleen weight. (B) Colon weight/length.?
Fig.3. Colon length in 4% DSS induced IBD model.
Fig.4 Representative histopathology image of each group.?
PBMC in vitro target screening
Fig1. Donor Screening in vivo.
?
TNBS-induced IBD mouse model and potency data of Anti-TL1A antibody
Fig2.?TNBS induced IBD model in PBMC construction model. (A) DAI score (B) Body weight change.
Fig3.?TNBS induced IBD model in PBMC construction model. (A) DAI score (B) Body weight change (D) Colon weight. (E) Colon length. (F) Colon weight/length.
Fig4. TNBS induced IBD model in PBMC construction model. (A) Representative HE images. (B) Histopathology score.?
Fig.1 Efficacy data of Duvakitug in DSS-Induced Chronic IBD Model in hTL1A mice. (A) Model construct schedule; (B) Clinical score; (C) AUC of clinical score.
Fig.2 Efficacy data of Duvakitug in DSS-Induced Chronic IBD Model in hTL1A mice. (A) Representative photographs of H&E -stained colon sections; (B) colon weight/ colon length; (C)pathology score.?
